Evolent Health placed on ‘Positive Catalyst Watch’ at JPMorgan

JPMorgan analyst Anne Samuel placed a “Positive Catalyst Watch” on shares of Evolent Health saying a “better than feared” earnings print on August 8 will serve as a positive catalyst. Commentary around utilization over the past few months from the large managed care providers have resulted in heightened level of concerns for Evolent, the analyst tells investors in a research note. The firm views the Q2 print as a “likely clearing event,” assuming Evolent Health can meet the guidance. It thinks much of the risk is now priced into the shares and keeps an Overweight rating on the name.